Medindia

X

Ceftaroline Will Earn Peak Year Sales of up to $200 Million in the Community-Acquired Pneumonia Drug Market

Tuesday, March 2, 2010 General News J E 4
Advertisement
Between 2010 and 2015, Ceftaroline is Poised to be the Only Marketed Anti-MRSA Cephalosporin for the Indication, According to New Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

ccomfort@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Philips Collaborates with Microsoft to Enhance Hea...
S
CVS Caremark Launches the Behavior Change Research...